Evidence map›Paper›PMID 29190964›Full record

ArticleOncotarget2017

Tumoral PD-L1 expression defines a subgroup of poor-prognosis vulvar carcinomas with non-viral etiology.

Thomas Hecking, Thore Thiesler, Cynthia Schiller, Jean-Marc Lunkenheimer, Tiyasha H Ayub, Andrea Rohr, Mateja Condic, Mignon-Denise Keyver-Paik, Rolf Fimmers, Jutta Kirfel and 3 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 4 pooled it
1.9field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 4 syntheses or guidelines pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors SWOG S1609: Vulvar Cancers.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Trial
  6. Article
  7. Review
  8. Clinical, histopathological and immunohistochemical analysis of vulvar squamous cell carcinoma.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2024
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Thomas Hecking *Department of Obstetrics and Gynecology, Center for Integrated Oncology, University of Bonn, Bonn, Germany.
Thore Thiesler *Institute of Pathology, Center for Integrated Oncology, University of Bonn, Bonn, Germany.
Cynthia SchillerInstitute of Pathology, Center for Integrated Oncology, University of Bonn, Bonn, Germany.
Jean-Marc LunkenheimerInstitute of Pathology, Center for Integrated Oncology, University of Bonn, Bonn, Germany.
Tiyasha H AyubDepartment of Obstetrics and Gynecology, Center for Integrated Oncology, University of Bonn, Bonn, Germany.
Andrea RohrDepartment of Obstetrics and Gynecology, Center for Integrated Oncology, University of Bonn, Bonn, Germany.
Mateja CondicDepartment of Obstetrics and Gynecology, Center for Integrated Oncology, University of Bonn, Bonn, Germany.
Mignon-Denise Keyver-PaikDepartment of Obstetrics and Gynecology, Center for Integrated Oncology, University of Bonn, Bonn, Germany.
Rolf FimmersInstitute of Medical Biometry, Informatics and Epidemiology, Center for Integrated Oncology, University of Bonn, Bonn, Germany.
Jutta KirfelInstitute of Pathology, Center for Integrated Oncology, University of Bonn, Bonn, Germany.
Walther KuhnDepartment of Obstetrics and Gynecology, Center for Integrated Oncology, University of Bonn, Bonn, Germany.
Glen Kristiansen *Institute of Pathology, Center for Integrated Oncology, University of Bonn, Bonn, Germany.
Kirsten Kübler *Department of Obstetrics and Gynecology, Center for Integrated Oncology, University of Bonn, Bonn, Germany.
University of Bonn · DEInstitut für Medizinische Biometrie, Informatik und Epidemiologie · DEMassachusetts General Hospital · USUniversity Hospital Bonn · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vulvar cancer is rare but incidence rates are increasing due to an aging population and higher frequencies of young women being affected. In locally advanced, metastatic or recurrent disease prognosis is poor and new treatment modalities are needed. Immune checkpoint blockade of the PD-1/PD-L1 pathway is one of the most important advancements in cancer therapy in the last years. The clinical relevance of PD-L1 expression in vulvar cancer, however, has not been studied so far. We determined PD-L1 expression, numbers of CD3

Indexed as

HPVimmune checkpointPD-L1prognostic factorvulvar cancer

Identifiers

PMID29190964
PMCPMC5696230
OpenAlexW2763868559

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.